Rhabdomyosarcoma 2-associated transcript (non-protein coding) (RMST)

Rhabdomyosarcoma 2-associated transcript (RMST) is a long non-coding RNA (lncRNA), typically comprising >200 nucleotides, and is not translated into protein. RMST is highly expressed in the brain and neural tissues, where it regulates neurogenesis, neuron differentiation, and survival through interactions with transcription factors (e.g., SOX2) and RNA-binding proteins (e.g., HuR, FUS, hnRNPA2/B1, hnRNPK). RMST also plays a key role in endothelial cell angiogenesis, promoting survival, proliferation, and migration, and its levels are significantly altered under hypoxic conditions. Pathologically, RMST acts as a tumor suppressor in several cancers and participates in neuropathic pain by regulating gene expression (notably DNMT3A methyltransferase) in damaged neurons. RMST knockdown or overexpression can modulate disease states, and RMST expression levels serve as biomarkers of prognosis and disease activity, but it is not currently a direct drug target—modulation involves RNA-based approaches.

Other names

NCRMSNCRNA00054LINC00054non-coding RNA in RMSnon-protein coding RNA 54long intergenic non-protein coding RNA 54non-coding RNA in rhabdomyosarcoma (RMS)rhabdomyosarcoma 2-associated transcript (non-coding RNA)rhabdomyosarcoma 2-associated transcript (non-protein coding)

Potential therapeutic manipulation of RMST expression (e.g., inhibition to suppress neuropathic pain, overexpression as tumor suppressor in cancer). Not classical drug-receptor/enzyme mechanisms—typically involves RNA interference, gapmers, or molecular tools targeting RNA.